New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
08:31 EDTFRXForest Labs completes $2.9B acquisition of Aptalis
Forest Laboratories announced the completion of its acquisition of Aptalis, a privately held specialty pharmaceutical company focused on gastrointestinal disorders and cystic fibrosis. The companies will begin combined operations today, with Aptalis operating as a subsidiary of Forest Laboratories. The acquisition of Aptalis strengthens Forestís gastrointestinal franchise in the U.S. and Canada, complements its growing cystic fibrosis business in Europe, and creates a cystic fibrosis business in the U.S. market. Forest expects the acquisition to add approximately $700M in revenue and about 78c per share to the companyís non-GAAP EPS in FY15. The acquisition also adds assets to Forestís pipeline in both therapeutic areas. Post-acquisition integration activities will begin today. As previously announced, Forest anticipates $125M in cost synergies by FY16.
News For FRX From The Last 14 Days
Check below for free stories on FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
16:08 EDTFRXActavis, Forest Labs receive second request under Hart-Scott-Rodino from FTC
Subscribe for More Information
April 9, 2014
05:50 EDTFRXForest Labs reports FDA provided feedback on combination aclidinium, formoterol
Forest Laboratories announced that they have recently received feedback from the FDA regarding the fixed dose combination of aclidinium and formoterol. Although no new issues have arisen, further discussion is needed with the Agency in order to address questions related to CMC, or Chemistry, Manufacturing and Control, and a Type C meeting with the FDA is going to be requested, likely to be held during Q3 this year. Forest and Almirall believe that the fixed dose combination of aclidinium and formoterol can be an important therapy for U.S. COPD patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use